Quinupristin-dalfopristin (RP 59500): An injectable streptogramin combination

American Journal of Health-System Pharmacy

Volumn 53, Issue 17, 1996, Pages 2045-2053

  Griswold, Maria W ^a   Lomaestro, Ben M ^b   Briceland, Laurie L ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

^c ACP

Author keywords

Antibiotics; Clinical studies; Dalfopristin; Drug administration routes; Injections; Mechanism of action; Pharmacokinetics; Quinupristin; Resistance; Toxicity

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; STREPTOGRAMIN; VANCOMYCIN;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ERYTHEMA; GRAM POSITIVE BACTERIUM; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PRURITUS; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 0029764281     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.17.2045     Document Type: Review

References (64)

1. Tailor SAN, Bailey EM, Rybak MJ. Enterococcus, an emerging pathogen. Ann Pharmacother. 1993; 27:1231-42.
2. Moellering RC Jr. Emergence of enterococcus as a significant pathogen. Clin Infect Dis. 1992; 14:1173-8.
3. Centers for Disease Control. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR. 1993; 42:597-9.
4. Etienne SD, Montay G, LeLiboux A et al. A Phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother. 1992; 30(suppl A):123-31.
5. Sanyal D, Johnson AP, George RC et al. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet. 1991; 337:54. Letter.
6. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992; 93:195-8.
7. Christensen KJ, Gubbins PO. Treatment of vancomycin-resistant staphylococcal infections. Ann Pharmacother. 1996; 30: 288-90.
8. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991; 35:553-9.
9. Andrews JM, Wise R. The in vitro activity of a new semisynthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. J Antimicrob Chemother. 1994; 33:849-53.
10. Rende-Fournier R, Leclercq R, Galimand M et al. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother. 1993; 37:2119-25.
11. Fantin B, Leclercq R, Merlé V et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother. 1995; 39:400-5.
12. Barry AL, Fuchs PC. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother. 1995; 39:238-40.
13. Turcotte A, Bergeron MG. Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots. Antimicrob Agents Chemother. 1992; 36:2211-5.
14. Nougayrede A, Berthaud N, Bouanchaud DH. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother. 1992; 30(suppl A):101-6.
15. Aumercier M, Bouhallab S, Capmau ML et al. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother. 1992; 30(suppl A):9-14.
16. Barrière JC, Bouanchaud DH, Paris JM et al. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother. 1992; 30(suppl A):1-8.
17. Bouanchaud DH. In vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother. 1992; 30(suppl A):95-9.
18. Fantin B, Leclercq R, Ottaviani M et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother. 1994; 38:432-7.
19. Berthaud N, Montay G, Conrad BJ et al. Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicemia. J Antimicrob Chemother. 1995; 36:365-73.
20. Herrera-Insua I, Jacques-Palaz K, Murray BE et al. Intracellular activity of RP59500 (quinupristin/dalfopristin), an injectable streptogramin, against Enterococcus faecium. Antimicrob Agents Chemother. 1996; 40:886-90.
21. Leclercq R, Nantas L, Soussy CJ et al. Activity of RP 59500, a new parenteral semisynthetic streptogramin against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992; 30(suppl A):67-75.
22. Chant C, Rybak MJ. Quinupristin/dalfopristin (RP59500): a new streptogramin antibiotic. Ann Pharmacother. 1995; 29: 1022-7.
23. Inoue M, Okamoto R, Okubo T et al. Comparative in vitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother. 1992; 30(suppl A):45-51.
24. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother. 1994; 33:1219-22.
25. Brumfitt W, Hamilton-Miller JMT, Shah S. In vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J Antimicrob Chemother. 1992; 30(suppl A):29-37.
26. Collins LA, Malanoski GJ, Eliopoulos GM et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993; 37:598-601.
27. Freeman C, Robinson A, Cooper R et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis. 1995; 21:47-50.
28. Caron F, Gold HS, Wennersten CB et al. Role of growth phase and erythromycin susceptibility on the bactericidal effect of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enteroccocus faecium. Paper presented at International Conference on Macrolides, Azalides, and Streptogramins. Lisbon, Portugal; 1996 Jan 26.
29. Fremaux A, Sissia G, Cohen R et al. In vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother. 1992; 30(suppl A):19-23.
30. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994; 38:2065-72.
31. Neu HC, Chin NX, Gu JW. The in vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone or in combination. J Antimicrob Chemother. 1992; 30(suppl A):83-94.
32. Pechère JC. In vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci. J Antimicrob Chemother. 1992; 30(suppl A):15-8.
33. Goto S, Miyazaki S, Kaneko Y. The in vitro activity of RP 59500 against gram-positive cocci. J Antimicrob Chemother. 1992; 30(suppl A):25-8.
34. Verbist L, Verhaegen J. Comparative in vitro activity of RP 59500. J Antimicrob Chemother. 1992; 30(suppl A:)39-44.
35. Soussey CJ, Acar JF, Cluzel R et al. A collaborative study of the in vitro sensitivity to RP 59500 of bacteria isolated in seven hospitials in France. J Antimicrob Chemother. 1992; 30(suppl A):53-8.
36. Hoban DJ, Weshnoweski B, Palatnick L et al. In vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J Antimicrob Chemother. 1992; 30(suppl A):59-65.
37. Aldridge KE, Schiro DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrob Agents Chemother. 1992; 36:854-5.
38. Archer GL, Auger P, Doern GV et al. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis. 1993; 16:223-6.
39. Silber JL, Patel M, Paul SM et al. Statewide surveillance of isolates of vancomycin-resistant gram-positive cocci: genotyping of vancomycin resistance and activity of RP 59500 (quinupristin-dalfopristin) and other antimicrobials. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL; 1994 Oct 5.
40. Casewell MW, Seyed-Akhavani, Wade J. In vitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to >512 mg/L of gentamicin. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1993 Oct 19.
41. Perri MB, Dembry LM, Zervos MJ. Comparative in vitro activity of RP 57669/RP 54476:RP 59500 against multi-drug resistant enterococci. Paper presented at International Conference on Macrolides, Azalides, and Streptogramins. Venice, Italy; 1994 Jan 19-22.
42. Shonekan D, Handwerger S, Mildvan D. Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, CP-99,219, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 20.
43. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococccus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1992; 36:856-9.
44. Tarasi A, Tomasz A. Activity of RP59500 against multidrug resistant clones of Streptococcus pneumoniae. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 20.
45. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP 59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother. 1993; 32:223-31.
46. Williams JD, Maskell JP, Shain H et al. Comparative in vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother. 1992; 30:27-37.
47. Jorgensen JH, McElmeel ML, Liaci JA. Activity of RP59500 and its components, quinupristin and dalfopristin, against Haemophilus influenzae. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 20.
48. Johnson DM, Erwin ME, Barrett MS et al. Antimicrobial activity of ten macrolide, lincosamine, and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis. 1992; 11:751-5.
49. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1993 Oct 18.
50. Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother. 1991; 35:1273-6.
51. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991; 35:1267-72.
52. Bernard E, Bensoussan M, Bensoussan F et al. Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/RP 54476). Eur J Clin Microbiol Infect Dis. 1994; 13:768-71.
53. Chambers HF. Studies of RP 59500 in vitro and in rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992; 30(suppl A):117-22.
54. Entenza JM, Drugeon H, Glauser MP et al. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother. 1995; 39:1419-24.
55. L'Hériteau F, Entenza JM, LaCassin F et al. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob Agents Chemother. 1995; 39:1425-9.
56. Hamilton-Miller JMT, Shah S, Smith CT. Comparative activity of RP 59500 (quinupristin-dalfopristin, an injectable streptogramin) and ciprofloxacin vs. Staphylococcus epidermidis in a biofilm model. Paper presented at International Conference on Macrolides, Azalides, and Streptogramins. Lisbon, Portugal; 1996 Jan 26.
57. Desnottes JE, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother. 1992; 30(suppl A):107-15.
58. Rakita RM, Jacques-Palaz K, Murray BE. Enterococcus faecium-neutrophil (PMN) interactions: resistance to phagocytosis is overcome by antibiotic pretreatment. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 18.
59. Synercid shows promise in treating resistant bacterial infections. Drug News Perspect. 1996; 9(1):48-9.
60. Lode H. Double-blind, randomised multicentre study of Synercid (RP59500) versus ceftriaxone in the treatment of acute gram-positive bacterial pneumonia. Paper presented at International Congress of Chemotherapy. Montreal, Quebec; 1995 Jul 18.
61. Lynn WA, Clutterbuck E, Want S et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium quinupristin/dalfopristin. Lancet. 1994; 344:1025-6. Letter.
62. Sahgal VS, Urban C, Mariano N et al. Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report. Microb Drug Resist. 1995; 1:245-7.
63. Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist. 1995; 1:95-6.
64. Lorian V, Fernandes E. Synergistic activity of injectable streptogramin RP 59500-vancomycin combination. Paper presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995 Sep 20.